Integrated assessment of malignancy in IDH ‐mutant astrocytoma with p16 and methylthioadenosine phosphorylase immunohistochemistry
Neuropathology · 2025
DOI: 10.1111/neup.13005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuropathology, 2025. Verfasst von Kenta Masui und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Tokyo Women's Medical University, Tokyo, Japan. Hauptthemen laut MEDLINE: Astrocytoma, Purine-Nucleoside Phosphorylase, Brain Neoplasms, Cyclin-Dependent Kinase Inhibitor p16. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science, Takeda Science Foundation, KAKENHI.
Abstract (Originalsprache)
In the fifth edition of the World Health Organization's (WHO) classification of tumors of the central nervous system (CNS), molecular analysis is required for not only determining each tumor type but assessing its prognosis based on malignancy (CNS WHO grade). A notable example is the loss of tumor suppressor gene cyclin‐dependent kinase inhibitor 2A ( CDKN2A ), and CDKN2A homozygous deletion (HD) is a novel CNS WHO grade 4 marker in isocitrate dehydrogenase gene ( IDH )‐mutant astrocytoma. However, incorporating molecular workup into the “routine diagnostics” of each brain tumor type remains a major challenge, especially in resource‐limited settings, including low‐ and middle‐income countries. We herein validated the usefulness of p16 and methylthioadenosine phosphorylase (MTAP) immunohistochemistry (IHC) as potential surrogates for the assessment of CDKN2A status in 20 IDH ‐mutant astrocytoma cases. Of note, loss or retention of p16 and MTAP could accurately predict CDKN2A HD (p16: 87.5%, MTAP: 88.9%) or non‐HD (p16: 100%, MTAP: 100%) with a single marker alone. Importantly, we revealed contributing factors to gray‐zone IHC results (p16: 5–20%, MTAP: mosaic), including (1) hemizygous deletion of CDKN2A , (2) degenerative findings, and (3) intratumoral CDKN2A HD heterogeneity, the detailed histologic and molecular assessment of which would be a key to achieving integrated assessment of malignancy in IDH ‐mutant astrocytoma. We characterized the pitfalls of each method and provided for the first time a practical flowchart of astrocytoma grading, contributing to a normalization of WHO2021‐based molecular diagnostics in resource‐limited settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Tokyo Women's Medical University, Tokyo, Japan.
- Department of Pathology, Kyorin University, Tokyo, Japan.
- Center for Advanced Medical Engineering Research and Development, Kobe University, Kobe, Japan.
- Department of Neurosurgery, Tokyo Women's Medical University Hospital, Tokyo, Japan.
- Department of Surgical Pathology, Tokyo Women's Medical University Hospital, Tokyo, Japan.
- Department of Laboratory Medicine and Pathology, Tokyo Metropolitan Neurological Hospital, Tokyo, Japan.
ORCID-Profile: Kenta Masui, Takashi Komori
Förderung
- Japan Society for the Promotion of Science
- Takeda Science Foundation
- KAKENHI
Zitieren
APA
Masui, K., Onizuka, H., Muragaki, Y., Kawamata, T., Nagashima, Y., Kurata, A., & Komori, T. (2025). Integrated assessment of malignancy in IDH ‐mutant astrocytoma with p16 and methylthioadenosine phosphorylase immunohistochemistry. Neuropathology. https://doi.org/10.1111/neup.13005
Vancouver
Masui K, Onizuka H, Muragaki Y, Kawamata T, Nagashima Y, Kurata A, et al. Integrated assessment of malignancy in IDH ‐mutant astrocytoma with p16 and methylthioadenosine phosphorylase immunohistochemistry. Neuropathology. 2025. doi:10.1111/neup.13005
BibTeX
@article{Masui2025,
author = {Masui, Kenta and Onizuka, Hiromi and Muragaki, Yoshihiro and Kawamata, Takakazu and Nagashima, Yoji and Kurata, Atsushi and Komori, Takashi},
title = {Integrated assessment of malignancy in IDH ‐mutant astrocytoma with p16 and methylthioadenosine phosphorylase immunohistochemistry},
journal = {Neuropathology},
year = {2025},
doi = {10.1111/neup.13005}
}
EUVIMED